Analyst Price Targets — COGT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 1, 2026 11:31 am | Laura Prendergast | Stifel Nicolaus | $45.00 | $34.96 | StreetInsider | Cogent (COGT) Reiterated at Buy by Stifel After ASCO Presentation on Bezuclastinib |
| May 6, 2026 10:14 am | Robert Burns | H.C. Wainwright | $55.00 | $36.98 | TheFly | Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright |
| February 19, 2026 1:55 pm | — | Robert W. Baird | $35.00 | $38.29 | TheFly | Cogent Biosciences price target raised to $35 from $34 at Baird |
| February 18, 2026 11:43 am | — | Piper Sandler | $52.00 | $37.62 | TheFly | Cogent Biosciences price target raised to $52 from $39 at Piper Sandler |
| January 7, 2026 5:41 am | Michael Yee | UBS | $60.00 | $34.78 | StreetInsider | UBS Starts Cogent (COGT) at Buy |
| January 6, 2026 11:09 am | — | H.C. Wainwright | $52.00 | $34.26 | TheFly | Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright |
| December 8, 2025 4:03 pm | — | Jefferies | $48.00 | $39.97 | TheFly | Cogent Biosciences price target raised to $48 from $45 at Jefferies |
| November 11, 2025 9:27 am | Chris Raymond | Raymond James | $60.00 | $32.46 | StreetInsider | Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite' |
| November 10, 2025 4:01 pm | — | Stifel Nicolaus | $40.00 | $34.97 | TheFly | Cogent upgraded to Buy at Stifel after 'overwhelmingly positive' GIST data |
| November 10, 2025 3:19 pm | David Nierengarten | Wedbush | $38.00 | $34.76 | TheFly | Wedbush upgrades Cogent to Outperform after better-than-expected trial results |
Latest News for COGT
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for AdvSM patients
Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis…
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16. 5 months versus 9. 2 months (HR=0. 50, CI: 0. 39-0.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for COGT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.